DCF Advisers’s Lifecore Biomedical LFCR Stock Holding History

DCF Advisers’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Hold	424,500	–	–	0.39%	43
2026 Q1	$1.58M	Sell	424,500 -17,500	-4%	-$121K	0.42%	44
2025 Q4	$3.62M	Sell	442,000 -10,000	-2%	-$74K	0.97%	31
2025 Q3	$3.33M	Sell	452,000 -10,987	-2%	-$83.1K	1.07%	29
2025 Q2	$3.76M	Sell	462,987 -20,013	-4%	-$135K	1.74%	20
2025 Q1	$3.4M	Sell	483,000 -56,989	-11%	-$354K	1.63%	20
2024 Q4	$4.01M	Buy	539,989 +251,511	+87%	+$1.61M	1.94%	18
2024 Q3	$1.42M	Sell	288,478 -2,206	-0.8%	-$11.5K	0.57%	39
2024 Q2	$1.49M	Buy	290,684 +6,000	+2%	+$35.5K	0.77%	37
2024 Q1	$1.51M	Buy	284,684 +25,000	+10%	+$179K	0.74%	31
2023 Q4	$1.61M	Buy	259,684 +138,930	+115%	+$965K	0.87%	29
2023 Q3	$911K	Buy	120,754 +33,254	+38%	+$304K	0.5%	45
2023 Q2	$846K	Buy	+87,500	New	+$534K	0.45%	43

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

DCF Advisers's LFCR Position: Q2 2026 in Review

DCF Advisers held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 424,500 shares worth $2.23M. The position accounts for 0.39% of the portfolio, ranked #43.

DCF Advisers first reported a position in LFCR in Q2 2023 and has held it in 13 quarters since. The position peaked at $4.01M in Q4 2024. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

DCF Advisers held 424,500 shares of Lifecore Biomedical worth $2.23M as of Q2 2026.
DCF Advisers left its Lifecore Biomedical share count unchanged in Q2 2026.
Lifecore Biomedical made up 0.39% of DCF Advisers's portfolio in Q2 2026, its #43 holding.
DCF Advisers first reported a position in Lifecore Biomedical in Q2 2023 and has held it in 13 quarters since.
DCF Advisers's Lifecore Biomedical position peaked at $4.01M in Q4 2024.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.